BioPharm Insight™ Investigative Journalist to Host Expert Panel Discussing Obesity Drugs in Development via Live Webinar on October 27, 2011

Share Article

Topics to be covered include Contrave and Qnexa, regulatory issues, emerging novel theories

On October 27, 2011 at 10am ET, BioPharm Insight North American Editor Elizabeth Krutoholow will moderate a live expert panel via online webinar discussing obesity drugs in development.

Featuring unbiased perspectives from subject matter experts Dr. Frank Greenway of Pennington Medical and Prof. Nick Finer of the University of Cambridge, the interactive and complimentary webinar will cover critical topics including:

  •     Agents currently in development such as Contrave (Orexigen) and Qnexa (Vivus)
  •     Regulatory landscape facing sponsors
  •     Emerging novel theories and trends from the Obesity Society's annual meeting
  •     Q&A session with attendees

To participate in the event, register online at:
Or, to request a recording, visit:

The discussion on obesity is presented as part of BioPharm Insight’s ongoing series of educational webinars. BioPharm Insight is published by Infinata, a Mergermarket company.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global life sciences community, combining forward-looking intelligence uncovered by an independent team of investigative journalists with the most comprehensive and powerful real-time database of market analytics and key contact information. BioPharm Insight is used by biopharma companies, CROs, service providers and financial markets firms to understand and interact with their industry. For a free trial of BioPharm Insight, visit

About Infinata
Infinata provides personalized technology solutions to help clients turn information into insight. Featuring exclusive biopharmaceutical intelligence and business development tools such as BioPharm Insight™ and BioPharm Clinical™, Infinata helps biopharma companies, CROs, service providers and financial markets firms understand and become active participants in their global industry. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson PLC. To learn more, visit

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kris Sarajian
Email >
Visit website